| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Division of Clinical Oncology, University of Wisconsin Medical School, Madison, Wisconsin
The distribution of 14C-labeled 8-methyl ether of xanthurenic acid (XAE), a human urinary metabolite of the amino acid tryptophan and a urinary bladder carcinogen for the mouse, was studied in mice. Four methods of administration were employed—surgical insertion into the bladder of a cholesterol pellet containing XAE, i.p. injection of XAE, direct instillation into the bladder lumen (i.u.), and s.c. injection into mice with (Group 1) and without (Group 2) cholesterol pellets in their bladders. Following surgical implantation of a pellet containing XAE, in 1–24 hr, 4–41% of the XAE was eluted from the pellets. Most of the 14C was retained in several tissues or was present in the gastrointestinal contents and feces. The urinary bladder retained much greater quantities of 14C than did other tissues. When an aqueous solution of XAE was placed i.u. into the mouse bladder, in 24 hr, nearly all disappeared from the bladder lumen. These data indicated that the bladder was permeable to XAE, and had ample opportunity for intimate contact with this compound during the acute period of exposure during the process of carcinogenesis.
Following s.c. administration of XAE to mice of Groups 1 and 2, in 24 hr, more than 95% of 14C was present in the urine, intestinal contents, feces, and CO2. The bladder specific activity in both groups was comparable. Thus differences in bladder carcinoma incidence observed previously for mice, similar to those in Groups 1 and 2, appeared unrelated to the quantity of XAE absorbed by the bladder following s.c. injection.
1 Supported in part by Grant No. CA-10017 from the National Cancer Institute, USPHS, and by Grants Nos. E-115 and E-116H from the American Cancer Society. Presented in part at the Ninth International Cancer Congress, Tokyo, Japan, October, 1966 (Abstracts, IX International Cancer Congress, 146, 1966).
Received 6/26/67. Accepted 10/18/67.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |